Status:
COMPLETED
DMT310-003 Topical in the Treatment of Acne Vulgaris
Lead Sponsor:
Dermata Therapeutics
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The objective is to evaluate the tolerability, safety, and efficacy of DMT310 topical powder mixed with diluent in male and female patients with moderate to severe facial acne vulgaris.
Eligibility Criteria
Inclusion
- Patient is male or non-pregnant female at least 12 years of age.
- Clinical diagnosis of moderate to severe acne vulgaris as determined by:
- Investigator's Global Assessment (IGA) at Randomization Patient has at least 20 inflammatory lesions on the face Patient has at least 20 noninflammatory lesions on the face
- Patient is willing to apply the Investigational Product as directed
- Patient is willing and able to comply with the protocol
Exclusion
- Patient is pregnant or planning to become pregnant
- Patient is taking a topical therapy on the face which may affect the patient's acne
Key Trial Info
Start Date :
October 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 4 2020
Estimated Enrollment :
181 Patients enrolled
Trial Details
Trial ID
NCT04106778
Start Date
October 10 2019
End Date
May 4 2020
Last Update
July 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dermata Investigational Site
Austin, Texas, United States, 78759